Head to Head Comparison: Imprimis Pharmaceuticals (IMMY) versus The Competition

Imprimis Pharmaceuticals (NASDAQ: IMMY) is one of 289 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Imprimis Pharmaceuticals to similar businesses based on the strength of its earnings, risk, valuation, dividends, institutional ownership, profitability and analyst recommendations.

Insider & Institutional Ownership

12.6% of Imprimis Pharmaceuticals shares are held by institutional investors. Comparatively, 49.8% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 12.6% of Imprimis Pharmaceuticals shares are held by company insiders. Comparatively, 16.8% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Imprimis Pharmaceuticals and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Imprimis Pharmaceuticals $19.94 million -$19.08 million -1.98
Imprimis Pharmaceuticals Competitors $290.27 million $35.99 million 53.59

Imprimis Pharmaceuticals’ peers have higher revenue and earnings than Imprimis Pharmaceuticals. Imprimis Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of current ratings and price targets for Imprimis Pharmaceuticals and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Imprimis Pharmaceuticals 0 0 1 0 3.00
Imprimis Pharmaceuticals Competitors 957 3407 11911 239 2.69

Imprimis Pharmaceuticals currently has a consensus price target of $5.00, suggesting a potential upside of 174.73%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 40.23%. Given Imprimis Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Imprimis Pharmaceuticals is more favorable than its peers.

Risk and Volatility

Imprimis Pharmaceuticals has a beta of -0.4, suggesting that its stock price is 140% less volatile than the S&P 500. Comparatively, Imprimis Pharmaceuticals’ peers have a beta of 2.51, suggesting that their average stock price is 151% more volatile than the S&P 500.


This table compares Imprimis Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Imprimis Pharmaceuticals -60.71% -264.98% -57.30%
Imprimis Pharmaceuticals Competitors -6,408.55% -84.01% -35.63%


Imprimis Pharmaceuticals peers beat Imprimis Pharmaceuticals on 9 of the 13 factors compared.

Imprimis Pharmaceuticals Company Profile

Imprimis Pharmaceuticals, Inc. (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Company is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Company also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas.

Receive News & Ratings for Imprimis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprimis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply